Charles River Labs Form 144: 4K shares slated for 6/23/25 sale

Rhea-AI Filing Summary

Form 144 filing for Charles River Laboratories International, Inc. (CRL) discloses a planned sale of 4,000 common shares through Merrill Lynch, valued at $550,000. The filer expects the transaction to occur on or about 06/23/2025. Total shares outstanding are reported at 49,115,712, so the proposed sale represents roughly 0.008% of the public float. The shares being sold were acquired on 06/02/2025 via an open-market purchase and will be settled for cash. No prior sales were reported in the past three months, and the form contains no remarks indicating special circumstances. The identity of the filer, their relationship to CRL, and any 10b5-1 plan details were not provided.

The filing is a routine notice of intent required under Rule 144 and does not, by itself, finalize the sale. Given the relatively small size versus market capitalization and the absence of additional context, the disclosure is likely to have limited market impact.

Positive

• None.

Negative

• Potential insider share sale—even though small, it reflects a seller reducing exposure to CRL.

Insights

Securities Analyst

TL;DR: Minor Rule 144 sale (4k shares, $550k) ≈0.008% float; limited valuation impact.

The Form 144 signals a potential insider or affiliate transaction but on a very small scale relative to CRL’s 49.1 million shares outstanding. The absence of the filer’s name, role, or any 10b5-1 notation means investors cannot assess motive or frequency of sales. With no accompanying earnings data or strategic commentary, the filing is informational only. Liquidity appears unaffected, and no negative operational insights are implied. I view the disclosure as neutral for valuation purposes.

Corporate Governance Expert

TL;DR: Governance neutral—routine compliance filing, no insider identity or unusual pattern.

Rule 144 filings help monitor insider activity, but governance concern arises only when sales are large, clustered, or timed around undisclosed events. Here, a single 4,000-share notice, with a standard broker and cash settlement, does not suggest governance red flags. The filer affirms no knowledge of undisclosed adverse information, aligning with SEC requirements. Lack of identifying details limits transparency, yet volume is immaterial. Therefore, I classify the impact as not significant.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St. Floor 37 New York NY 10281	4000	550000.00	49115712	06/23/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/02/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			4000	06/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the size of the proposed CRL share sale in this Form 144?

The filer intends to sell 4,000 common shares of Charles River Laboratories International, Inc.

What is the approximate market value of the shares to be sold?

The aggregate market value disclosed is $550,000.

When is the planned sale date for the CRL shares?

The filer lists an approximate sale date of 06/23/2025.

How many CRL shares are currently outstanding according to the filing?

The form states 49,115,712 shares are outstanding.

What percentage of outstanding shares does the 4,000-share sale represent?

About 0.008% of the total shares outstanding, indicating minimal dilution or market impact.

Were any CRL shares sold by this filer in the past three months?

No; the “Securities Sold During the Past 3 Months” section reports nothing to disclose.